The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Variation in ANGPTL4 and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
ANGPTL4 deficiency in humans is associated with higher circulating HDL-cholesterol levels.
“ANGPTL4 deficiency in humans is associated with higher circulating HDL-cholesterol (HDL-C) levels (56, 58, 91, 92),”
From Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8 (2021) · cites this paper as [92]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging.
Pignoli, P., Tremoli, E., Poli, A., Oreste, P., & Paoletti, R. (1986) · Circulation · doi:10.1161/01.cir.74.6.1399 · Cited by 2,404
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Variations in DNA elucidate molecular networks that cause disease
Chen, Y., Zhu, J., Lum, P. Y., Yang, X., Pinto, S., MacNeil, D. J., Zhang, C., Lamb, J., Edwards, S., Sieberts, S. K., et al. (2008) · Nature · doi:10.1038/nature06757 · Cited by 887
Köster, A., Chao, Y. B., Mosior, M., Ford, A., Gonzalez-DeWhitt, P. A., Hale, J. E., Li, D., Qiu, Y., Fraser, C. C., Yang, D. D., et al. (2005) · Endocrinology · doi:10.1210/en.2005-0476 · Cited by 427 · cited 2×
“Conversely, an ANGPTL4 knockout mouse has reduced plasma triglyceride concentrations because of increased VLDL clearance and decreased VLDL production and has modestly lower cholesterol levels [15,17].”
Flagged first, then by citations
Research works printed but not linked: 13
- Romeo, 2007, Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL, Nat Genet, 39, 513, 10.1038/ng1984 · DOI · Paper page
- The ARIC Investigators, 1989, The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives, Am J Epidemiol, 129, 687, 10.1093/oxfordjournals.aje.a115184 · DOI
- Friedewald, 1972, Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge, Clin Chem, 18, 499, 10.1093/clinchem/18.6.499 · DOI · Paper page
- 1997, The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus, Diabetes Care, 20, 1183, 10.2337/diacare.20.7.1183 · DOI · Paper page
- Baecke, 1982, A short questionnaire for the measurement of habitual physical activity in epidemiological studies, Am J Clin Nutr, 36, 936, 10.1093/ajcn/36.5.936 · DOI
- Mundt, 1992, Measuring ankle systolic blood pressure: validation of the Dinamap 1846 SX, Angiology, 43, 555, 10.1177/000331979204300703 · DOI
- The National Survey of Stroke, 1981, National Institute of Neurological and Communicative Disorders and Strokes, Stroke, 12, I
- Yoshida, 2002, Angiopoietin-like protein 4 is a potent hyperlipidemia-inducing factor in mice and inhibitor of lipoprotein lipase, J Lipid Res, 43, 1770, 10.1194/jlr.C200010-JLR200 · DOI · Paper page
- Desai, 2007, Lipid-lowering effects of anti-angiopoietin–like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice, Proc Natl Acad Sci U S A, 104, 11766, 10.1073/pnas.0705041104 · DOI · Paper page
- Lichtenstein, 2007, Angptl4 upregulates cholesterol synthesis in liver via inhibition of LPL- and HL-dependent hepatic cholesterol uptake, Arterioscler Thromb Vasc Biol, 27, 2420, 10.1161/ATVBAHA.107.151894 · DOI · Paper page
- Sukonina, 2006, Angiopoietin-like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue, ProcNatl Acad Sci U S A, 103, 17450, 10.1073/pnas.0604026103 · DOI · Paper page
- Yost, 1993, Tissue-specific lipoprotein lipase: relationships to body composition and body fat distribution in normal weight humans, Obes Res, 1, 1, 10.1002/j.1550-8528.1993.tb00002.x · DOI
- Cambien, 2007, Genetics of cardiovascular diseases: from single mutations to the whole genome, Circulation, 116, 1714, 10.1161/CIRCULATIONAHA.106.661751 · DOI
Cited by
Sorted by citations
Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease
Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885
Sandesara, P. B., Virani, S. S., Fazio, S., & Shapiro, M. D. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00184 · Cited by 608
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease
Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493
Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease
Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497
Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease
Rosenson, R. S., Davidson, M. H., Hirsh, B. J., Kathiresan, S., & Gaudet, D. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.042 · Cited by 260
Triglyceride-rich lipoproteins as a causal factor for cardiovascular disease
Toth, P. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s104369 · Cited by 237
Vallejo-Vaz, A. J., Fayyad, R., Boekholdt, S. M., Hovingh, G. K., Kastelein, J. J., Melamed, S., Barter, P., Waters, D. D., & Ray, K. K. (2018) · Circulation · doi:10.1161/circulationaha.117.032318 · Cited by 187
Surprises from genetic analyses of lipid risk factors for atherosclerosis
Musunuru, K., & Kathiresan, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306398 · Cited by 159
Regulation of lipoprotein metabolism by ANGPTL3, ANGPTL4, and ANGPTL8
Sylvers-Davie, K. L., & Davies, B. S. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00195.2021 · Cited by 154
Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease?
Olshan, D. S., & Rader, D. J. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.01.012 · Cited by 30
Metadata
- Authors
- Folsom, A. R., Peacock, J. M., Demerath, E., & Boerwinkle, E.
- Venue
- Metabolism
- Publisher
- Elsevier BV
- Published
- 2008-11
- Volume
- 57
- Issue
- 11
- Pages
- 1591-1596
- ISSN
- 0026-0495
- PMC
- PMC2707767
- Cited by
- 64
- References
- 4
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review